In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content.
In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss:
- Company origins, focus, and fundraising performance to date
- Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity
- Performance of ICT01, Imcheck’s clinical-stage lead program targeting BTN3A in gamma-delta T-cells
- Positioning and commercial strategy in the post-PD1 solid-tumor landscape
Episode Guests:
- Pierre d’Epenoux, CEO, ImCheck Therapeutics
- Paul Frohna, CMO, ImCheck Therapeutics
©2023 Lumanity Inc.
